LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it will be presenting results from its clinical trial of ICT-107 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.
